Aclaris Therapeutics (ACRS) versus Praxsyn (OTCMKTS:PXYN) Financial Survey

Praxsyn (OTCMKTS:PXYN) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Profitability

This table compares Praxsyn and Aclaris Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Praxsyn N/A N/A N/A
Aclaris Therapeutics -1,578.24% -63.74% -56.49%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Praxsyn and Aclaris Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxsyn 0 0 0 0 N/A
Aclaris Therapeutics 0 0 3 0 3.00

Aclaris Therapeutics has a consensus target price of $45.33, indicating a potential upside of 548.55%. Given Aclaris Therapeutics’ higher probable upside, analysts clearly believe Aclaris Therapeutics is more favorable than Praxsyn.

Earnings & Valuation

This table compares Praxsyn and Aclaris Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Praxsyn N/A N/A N/A N/A N/A
Aclaris Therapeutics $1.68 million 170.32 -$68.52 million ($2.50) -2.80

Praxsyn has higher earnings, but lower revenue than Aclaris Therapeutics.

Risk and Volatility

Praxsyn has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.

Institutional & Insider Ownership

72.6% of Aclaris Therapeutics shares are owned by institutional investors. 17.0% of Aclaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aclaris Therapeutics beats Praxsyn on 6 of the 9 factors compared between the two stocks.

About Praxsyn

Praxsyn Corporation, a health care company, provides medical practitioners with medications and services for their patients. It formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents in the forms of transdermal creams, patches, and oral capsules for pain management, erectile dysfunction, and metabolic therapies. Praxsyn Corporation provides its products to patients covered under the California workers' compensation system, as well as preferred provider contracts. The company was formerly known as The PAWS Pet Company, Inc. and changed its name to Praxsyn Corporation in March 2014. Praxsyn Corporation was founded in 2005 and is headquartered in Las Vegas, Nevada.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.

Receive News & Ratings for Praxsyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxsyn and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply